SAN DIEGO, July 30 /PRNewswire/ — Conatus
Pharmaceuticals Inc. announced today that Conatus acquired the Idun
Pharmaceuticals subsidiary of Pfizer Inc. Financial terms
were not disclosed. Conatus Pharmaceuticals is a
privately-held drug development company focused on liver disease
and oncology.
Conatus Pharmaceuticals is led by Steven
J. Mento, Ph.D., the former CEO of Idun Pharmaceuticals,
which was acquired by Pfizer Inc. in 2005. “The addition of
Idun to Conatus continues our important work in liver disease and
expands our therapeutic reach into oncology,” said Dr. Mento.
“Conatus plans to leverage its scientific and drug
development expertise and resources to continue to advance
potentially important therapeutic candidates in liver disease and
oncology.”
Idun Pharmaceuticals was a privately-held biopharmaceutical
company engaged in the discovery and development of drug candidates
to control apoptosis. At the time of the acquisition by Pfizer,
Idun had a Phase 2 drug candidate in liver disease
(emricasan/IDN-6556), preclinical drug candidates including
IDN-13389 for oncology, a development agreement with Abbott for an
oncology drug candidate, and key intellectual property in the field
of apoptosis. Conatus’ SVP Corporate Development, Jennifer Giottonini Cayer added, “We
appreciate the contributions of Pfizer’s colleagues on these
potentially important drug candidates. Conatus is excited to
have the opportunity to work on these programs.”
Conatus Pharmaceuticals Inc. is a privately-held pharmaceutical
company engaged in the development of innovative human therapeutics
to treat liver disease and oncology. The lead drug candidate,
CTS-1027 is in multiple Pha
‘/>”/>
